Kosuge Masami, Kimura Kazuo, Ishikawa Toshiyuki, Ebina Toshiaki, Hibi Kiyoshi, Tsukahara Kengo, Kanna Masahiko, Iwahashi Noriaki, Okuda Jyun, Nozawa Naoki, Ozaki Hiroyuki, Yano Hideto, Kusama Ikuyoshi, Umemura Satoshi
The Division of Cardiology, Yokohama City University Medical Center, Yokohama, Japan.
Am J Cardiol. 2006 Feb 1;97(3):334-9. doi: 10.1016/j.amjcard.2005.08.049.
Many studies have shown that ST-segment depression is a strong predictor of poor outcomes in patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACSs); however, lead aVR was not considered in these studies. The present study examined the prognostic usefulness of the 12-lead electrocardiogram in combination with biochemical markers in 333 patients with NSTE-ACS. ST-segment deviation of > or =0.5 mm was considered clinically significant. Coronary angiography was performed a median of 3 days after admission in all patients. The primary end point was the composite of death, myocardial infarction, and urgent revascularization at 90 days. ST-segment elevation in lead aVR (odds ratio 13.8, 95% confidence interval 1.43 to 100.9, p = 0.03) and increased troponin T (odds ratio 7.9, 95% confidence interval 1.22 to 123.8, p = 0.04) were the only independent predictors of restricted events (death or myocardial infarction) at 90 days. ST-segment elevation in lead aVR (odds ratio 12.8, 95% confidence interval 4.80 to 33.9, p < 0.0001) and increased troponin T (odds ratio 2.03, 95% confidence interval 1.20 to 4.29, p = 0.04) were also the only independent predictors of adverse events (death, myocardial infarction, or urgent revascularization) at 90 days. When ST-segment status in lead aVR was combined with troponin T, patients with ST-segment elevation in lead aVR and increased troponin T had the highest rates of left main or 3-vessel coronary disease (62%) and 90-day adverse outcomes (47%). In conclusion, our findings suggest that ST-segment status in lead aVR combined with troponin T on admission is a simple and useful clinical tool for early risk stratification in patients with NSTE-ACS.
许多研究表明,ST段压低是预测非ST段抬高型急性冠脉综合征(NSTE-ACS)患者预后不良的有力指标;然而,这些研究未考虑aVR导联。本研究在333例NSTE-ACS患者中,检验了12导联心电图联合生化标志物的预后价值。ST段偏移≥0.5mm被视为具有临床意义。所有患者入院后中位3天进行冠状动脉造影。主要终点是90天时死亡、心肌梗死和紧急血运重建的复合终点。aVR导联ST段抬高(比值比13.8,95%置信区间1.43至100.9,p = 0.03)和肌钙蛋白T升高(比值比7.9,95%置信区间1.22至123.8,p = 0.04)是90天时受限事件(死亡或心肌梗死)的仅有的独立预测因素。aVR导联ST段抬高(比值比12.8,95%置信区间4.80至33.9;p < 0.0001)和肌钙蛋白T升高(比值比2.03,95%置信区间1.20至4.29,p = 0.04)也是90天时不良事件(死亡、心肌梗死或紧急血运重建)的仅有的独立预测因素。当aVR导联ST段状态与肌钙蛋白T相结合时,aVR导联ST段抬高且肌钙蛋白T升高的患者左主干或三支血管病变发生率最高(62%),90天不良结局发生率最高(47%)。总之,我们的研究结果表明,入院时aVR导联ST段状态联合肌钙蛋白T是NSTE-ACS患者早期风险分层的一种简单且有用的临床工具。